ABOS•benzinga•
Acumen Pharmaceuticals Completes Enrollment In ALTITUDE-AD Phase 2 Clinical Trial Of ACU193 In Early Alzheimer's Disease, Plans To Report Topline Results, Including Efficacy And Safety Data, In Late 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga